125 related articles for article (PubMed ID: 16541186)
1. Torcetrapib and atorvastatin: a novel combination therapy for dyslipidemia.
Zareba G
Drugs Today (Barc); 2006 Feb; 42(2):95-102. PubMed ID: 16541186
[TBL] [Abstract][Full Text] [Related]
2. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.
Bots ML; Visseren FL; Evans GW; Riley WA; Revkin JH; Tegeler CH; Shear CL; Duggan WT; Vicari RM; Grobbee DE; Kastelein JJ;
Lancet; 2007 Jul; 370(9582):153-160. PubMed ID: 17630038
[TBL] [Abstract][Full Text] [Related]
3. Effect of torcetrapib on the progression of coronary atherosclerosis.
Nissen SE; Tardif JC; Nicholls SJ; Revkin JH; Shear CL; Duggan WT; Ruzyllo W; Bachinsky WB; Lasala GP; Tuzcu EM;
N Engl J Med; 2007 Mar; 356(13):1304-16. PubMed ID: 17387129
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
McKenney JM; Davidson MH; Shear CL; Revkin JH
J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250
[TBL] [Abstract][Full Text] [Related]
5. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
Kastelein JJ; van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL; Duggan WT; Bots ML;
N Engl J Med; 2007 Apr; 356(16):1620-30. PubMed ID: 17387131
[TBL] [Abstract][Full Text] [Related]
6. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
Teramoto T; Takeuchi M; Morisaki Y; Ruotolo G; Krueger KA
Am J Cardiol; 2014 Jun; 113(12):2021-9. PubMed ID: 24786356
[TBL] [Abstract][Full Text] [Related]
8. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.
Brousseau ME; Diffenderfer MR; Millar JS; Nartsupha C; Asztalos BF; Welty FK; Wolfe ML; Rudling M; Björkhem I; Angelin B; Mancuso JP; Digenio AG; Rader DJ; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1057-64. PubMed ID: 15761191
[TBL] [Abstract][Full Text] [Related]
9. Effects of torcetrapib in patients at high risk for coronary events.
Barter PJ; Caulfield M; Eriksson M; Grundy SM; Kastelein JJ; Komajda M; Lopez-Sendon J; Mosca L; Tardif JC; Waters DD; Shear CL; Revkin JH; Buhr KA; Fisher MR; Tall AR; Brewer B;
N Engl J Med; 2007 Nov; 357(21):2109-22. PubMed ID: 17984165
[TBL] [Abstract][Full Text] [Related]
10. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
11. HDL metabolism and CETP inhibition.
Barkowski RS; Frishman WH
Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.
Hovingh GK; Kastelein JJ; van Deventer SJ; Round P; Ford J; Saleheen D; Rader DJ; Brewer HB; Barter PJ
Lancet; 2015 Aug; 386(9992):452-60. PubMed ID: 26047975
[TBL] [Abstract][Full Text] [Related]
13. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
16. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
18. Torcetrapib + atorvastatin (Pfizer).
Burnett JR
Curr Opin Investig Drugs; 2005 Sep; 6(9):944-50. PubMed ID: 16187694
[TBL] [Abstract][Full Text] [Related]
19. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway.
Catalano G; Julia Z; Frisdal E; Vedie B; Fournier N; Le Goff W; Chapman MJ; Guerin M
Arterioscler Thromb Vasc Biol; 2009 Feb; 29(2):268-75. PubMed ID: 19038848
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of Korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg.
Lee CW; Baek SH; Hong TJ; Choi YJ; Kim YJ; Ahn TH; Ihm SH; Bae JH; Hong SJ; Kim DI; Ahn YK; Hur SH; Park DG; Choi DJ; Lee SU; Kim BS; Ryu KH; Jang YS; Lee SH; Seung KB; Kim HS
Cardiovasc Drugs Ther; 2010 Apr; 24(2):181-8. PubMed ID: 20383571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
